Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB080 in early Alzheimer's disease
jRCT2031220635Active, not recruiting
- Sponsor
- Biogen
- Start
- Jul 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Randomised, double-blind trial of biib080 in Alzheimer's disease (AD) (4 arms), sponsored by Biogen. Primary endpoint: Dose-response in change from baseline to Week 76 on the CDR-SB. Started Jul 2023; status: active, not recruiting.
02
Drugs
biib080
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031220635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220635.